Eyenovia Announces First Commercial Sale Of Mydcombi
Portfolio Pulse from Happy Mohamed
Eyenovia, Inc. (NASDAQ:EYEN) has announced the first commercial sale of Mydcombi, the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation. The initial sale was to Dr. Nathan M. Radcliffe, a renowned ophthalmologist. Mydcombi is designed to streamline the estimated 106 million office-based comprehensive eye exams with pupil dilation performed every year in the United States.
August 04, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eyenovia's first commercial sale of Mydcombi validates its proprietary Optejet dispensing platform and could potentially boost its revenues.
The first commercial sale of Mydcombi represents a significant milestone for Eyenovia as it validates the company's proprietary Optejet dispensing platform. This could potentially lead to increased revenues for the company as Mydcombi is designed to streamline a large number of office-based comprehensive eye exams performed every year in the United States.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100